# Selank Peptide

> Selank is a tuftsin-derived peptide with a Pro-Gly-Pro tail that targets anxiety response, stress resilience, immune signaling, and cognition pathways.

Canonical: https://pepflow.app/peptides/selank/

The Tuftsin Analog

Selank is a synthetic peptide analog of tuftsin extended with a Pro-Gly-Pro sequence. It is best known from Russian neuropeptide literature for anxiety, mood, and cognition-adjacent research.

Brain health  Stress and sleep

Tier C

Evidence Emerging

Safety Limited Data

FDA status Not Approved

Last reviewed August 11, 2026 24 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Selank?

Selank is a synthetic peptide analog of tuftsin extended with a Pro-Gly-Pro sequence. It is best known from Russian neuropeptide literature for anxiety, mood, and cognition-adjacent research.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>)

Its identity is immune-neuropeptide hybrid: tuftsin biology gives the immune-signaling origin, while the marketed use case is usually intranasal anxiolytic or stress support.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>)

Selank needs separation from Semax. They are often paired, but they have different sequences, target stories, and practical intent.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>)

## What Selank is investigated for

Selank evidence is grouped by practical use case and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Anxiety reduction without sedation Intranasal 55% Emerging

Anxiety reduction has Selank’s most direct human-facing evidence, but not a large international approval program.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>)

#### Human evidence

A human generalized-anxiety and neurasthenia publication supports Selank as an anxiolytic candidate, with regional and study-quality limits.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>)

#### Animal / mechanistic evidence

Tuftsin-analog reviews and adaptive-behavior studies support anxiolytic mechanism plausibility.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>)

### ### Immune modulation Intranasal 52% Emerging

Immune modulation is distinct from Selank anxiolytic claims and depends on limited human and mechanistic evidence.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/21786679/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

#### Human evidence

A human anxiety-asthenic-disorder study reported immunomodulatory effects of Selank.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/21786679/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

#### Animal / mechanistic evidence

Gene-expression studies report changes in chemokine, cytokine, and receptor expression after Selank and its fragments.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/21786679/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

### ### Stress resilience Intranasal 42% Preliminary

Stress resilience is plausible but less clinically developed than anxiety reduction.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16963804/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

#### Human evidence

Direct modern human stress-resilience trials are not established in the cited literature.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16963804/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

#### Animal / mechanistic evidence

Adaptive-behavior and tuftsin-analog studies support a stress-response rationale.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16963804/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

### ### Cognitive support during stress Intranasal 34% Limited

Cognitive support should be framed around stress models, not as broad nootropic proof.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/18661785/>)

#### Human evidence

Direct human cognitive-enhancement outcomes for Selank are not established in the cited literature.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/18661785/>)

#### Animal / mechanistic evidence

Rat memory-impairment and stress-behavior publications support cognition discussion only in stress or impairment contexts.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/14969422/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/18661785/>)

## Evidence snapshot

### Overall confidence

Emerging

55%

Selank has limited-human support for intranasal anxiolytic and stress-response use, mostly from regional literature. Cognition and sleep uses remain secondary.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

55%

### Human evidence

Emerging

Regional clinical literature supports anxiolytic interest, but major-market approval evidence is absent.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

34%

### Animal / preclinical

Limited

Mechanistic work supports stress, immune, and neurotransmitter plausibility.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

55%

### Mechanism support

Emerging

Selank is discussed around GABAergic, monoamine, immune, and stress-response biology. The mechanism suggests anxiety-signal modulation without classic benzodiazepine sedation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

## Forms & administration

Selank is tracked as an intranasal stress-regulation peptide. Spray-style use is separate from injectable dosing and from Semax combinations.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

Nasal spray

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Intranasal protocols use 250-400 mcg per day. Injectable protocols use about 250 mcg per dose.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

### Frequency

Intranasal protocols use 1-2 sessions daily. Injectable protocols use 1 dose daily.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

### Timing Considerations

Common timing is afternoon or evening.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

### Cycle Length

Common cycles run 2-6 weeks.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

[Full Selank dosage guide](<https://pepflow.app/peptides/selank/dosage/>)

## What to expect

### First few days

Intranasal Selank may feel like calmer focus, easier stress recovery, steadier mood, or smoother sleep transition.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>) [\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>)

### Weeks 2-4

Intranasal stress-regulation effects may appear as calmer anxiety frequency, steadier mood, smoother sleep continuity, or easier stress recovery.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>) [\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>)

### After stopping

Stress and anxiety patterns may drift back toward baseline routines after intranasal Selank use ends.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>) [\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>)

## Safety profile

Selank safety is mainly intranasal and neuroactive: nasal irritation, fatigue, headache, sedative overlap, and psychiatric context matter.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

### Common side effects

- Nasal irritation [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- Fatigue [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- Headache [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

### Cautions

- Sedatives / anxiolytics[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- Psychiatric medications[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- Formulation variability[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

### What we don't know

Long-term intranasal use, medication interactions, pregnancy, and pediatric safety remain poorly characterized in major-market sources.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

## Who Selank is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Pregnancy or breastfeeding warrants medical review or avoidance for Selank.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- **Unstable psychiatric symptoms**

  Unstable psychiatric symptoms warrants medical review or avoidance for Selank.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- **Use with sedatives or anxiolytics without clinician review**

  Use with sedatives or anxiolytics without clinician review warrants medical review or avoidance for Selank.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Sedatives / anxiolytics / alcohol**

  Benzodiazepines, alcohol, sleep aids, or sedating supplements can compound calming effects or reduce alertness; this is a theoretical neuroactive caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- **Psychiatric medications**

  SSRIs, SNRIs, antipsychotics, or mood stabilizers can make anxiety, mood, or sleep changes harder to attribute; this is a theoretical neuroactive caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- **Other nasal sprays**

  Decongestant, steroid, or irritating nasal sprays can add local irritation or change intranasal tolerability; this is a route-specific caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

## Pairing notes

### Commonly included in these stacks

[**Semax / Selank** Semax / Selank is a two-neuropeptide stack built around focus, cognitive stress response, and anxiety-oriented support. Semax supplies the ACTH-fragment cognitive and neuroprotective rationale, while Selank supplies the tuftsin-analog anxiolytic and stress-resilience rationale. Semax Selank](<https://pepflow.app/stacks/semax-selank/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, Selank is not FDA-approved for the reviewed intranasal route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Intranasal | Not Approved · Selank is not FDA-approved as an intranasal drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Flagged · FDA safety-risk materials flag selank acetate for immunogenicity, aggregation, peptide impurities, and missing human safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Intranasal

FDA drug approval

Not Approved

Selank is not FDA-approved as an intranasal drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Flagged

FDA safety-risk materials flag selank acetate for immunogenicity, aggregation, peptide impurities, and missing human safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[17\]](<https://www.ema.europa.eu/en/medicines>) [\[18\]](<https://products.mhra.gov.uk/>) [\[19\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[20\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Selank intranasal route as athlete-cleared without sport-specific review.[\[12\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[15\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

Selank is a tuftsin-derived peptide discussed around GABAergic tone, monoamine signaling, immune modulation, and stress-response biology. In plain terms, the proposed mechanism is anxiety-signal regulation without the same direct sedative pathway as benzodiazepines.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

Intranasal delivery is part of the mechanism interpretation because nasal formulation and central exposure determine whether the peptide reaches the relevant signaling environment. Psychiatric history, concurrent medications, and limited route-matched outcomes keep mood claims narrower than the mechanism story. That keeps the section anchored to biology rather than broad anxiolytic certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

## Research gaps & open questions

What the current literature has not yet settled about Selank:

01

Large randomized trials in major healthcare systems need to show whether Selank reduces anxiety or improves daily functioning compared with placebo and standard treatments.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

02

Studies have not established how Selank interacts with antidepressants, benzodiazepines, sleep medicines, stimulants, or other psychiatric drugs.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

03

Semax and Selank need to be studied together before their combined benefits, side effects, dose, and timing can be judged.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

## Common questions

### Is Selank FDA-approved in the United States?

No. Selank is not FDA-approved in the U.S. for intranasal drug use, and FDA lists selank acetate with compounding safety concerns.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

### Is Selank a benzodiazepine?

No. Selank is a tuftsin-derived peptide, not a benzodiazepine, but mood-medication interactions still matter.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

### Is the Semax/Selank stack proven?

No. The pairing is common in peptide forums, but intranasal combination efficacy, safety, and dosing have not been established.[\[10\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>) [\[11\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)

## Myths & misconceptions

### Myth

Non-sedating claims mean there is no mood risk.

### Reality

Any neuroactive compound can still affect anxiety, sleep, activation, or medication response.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

### Myth

Selank is basically Semax.

### Reality

They are different peptides with different intent and mechanism stories.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

## History & discovery

Selank was developed from tuftsin-related peptide biology and regional anxiolytic research. Its origin story connects immune peptide design with neuropsychotropic claims, rather than classic sedative drug development. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

Human anxiety and neurasthenia studies positioned Selank as a peptide anxiolytic with possible mechanisms beyond benzodiazepine sedation. That shaped its stress-regulation identity.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

Reviews and animal studies tied Selank to tuftsin analogy, immune signaling, memory, and BDNF-related pathways. These milestones widened the story but did not validate combination stacks.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/18454096/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30255741/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/18577961/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)

## Published research 24 citations

- [\[1\] **\[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia\].** Zh Nevrol Psikhiatr Im S S Korsakova, 2008. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/18454096/>)
- [\[2\] **Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.** Protein Pept Lett, 2018. review.](<https://pubmed.ncbi.nlm.nih.gov/30255741/>)
- [\[3\] **\[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders\].** Zh Nevrol Psikhiatr Im S S Korsakova, 2008. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/18577961/>)
- [\[4\] **Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.** Bull Exp Biol Med, 2019 Sep. animal.](<https://pubmed.ncbi.nlm.nih.gov/31625062/>)
- [\[5\] **\[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice\].** Zh Vyssh Nerv Deiat Im I P Pavlova, 2008 Mar-Apr. animal.](<https://pubmed.ncbi.nlm.nih.gov/18661785/>)
- [\[6\] **Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.** Neurosci Behav Physiol, 2003 Nov. animal.](<https://pubmed.ncbi.nlm.nih.gov/14969422/>)
- [\[7\] **Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight.** Pharmacol Rep, 2006 Jul-Aug. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/16963804/>)
- [\[8\] **\[Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments\].** Genetika, 2011 May. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/21786679/>)
- [\[9\] **\[The characteristics of the anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism in the brain of rats with chronic deprivation of serotoninergic system activity\].** Eksp Klin Farmakol, 1995 Nov-Dec. animal.](<https://pubmed.ncbi.nlm.nih.gov/8704608/>)
- [\[10\] **Drugs@FDA/openFDA query for Selank** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Selank%22&limit=1>)
- [\[11\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[12\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[13\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[14\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[15\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[16\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[17\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[18\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[19\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[20\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[21\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[22\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[23\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[24\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Neuroactive peptide

**Tier**

C

**Evidence**

55% Emerging

**Safety**

Limited Data

**FDA status**

Not Approved

**Intranasal 503A**

Flagged

**Citations**

[24 citations](<https://pepflow.app/peptides/selank/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Anxiety reduction without sedation
- Immune modulation
- Stress resilience
- Cognitive support during stress

### Common side effects

- Nasal irritation
- Fatigue
- Headache

### Also known as

- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Tuftsin analog
- Selanc

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Selank dosage guide](<https://pepflow.app/peptides/selank/dosage/>)
- [Semax / Selank](<https://pepflow.app/stacks/semax-selank/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
